Established on 17 December 1997, Actelion Pharmaceuticals specialises in offering solution for various medical needs. Based in Switzerland, the company supplies their products to over 25 countries, including Australia.
Actelion Pharmaceuticals offers Tracleer Tablets to treat pulmonary arterial hypertension functional class II – IV. Dual endothelin receptor antagonists, Tracleer tablets aid in improving exercise capacity and reducing the rate of clinical worsening. They are an oral treatment approved for the chronic disease, pulmonary arterial hypertension (PAH). Lungs and heart of the person, who is suffering from this disease, will be affected. Tracleer has been accepted in more 50 countries as an effective treatment for PAH. It is also proven to effective for treating digital ulcer disease in systemic sclerosis patients.
Tracleer Tablets have to be taken based on the doctors’ advice. Adults are suggested to consume 62.5 mg twice daily for first four weeks. Based on how the patient reacts to these tablets, they will be advised to take 125 mg twice daily. Only 2 mg is recommended for children and patients with low body weight. These tablets have to be swallowed with water in the morning and evening.